ARS Pharmaceuticals announced pre-ordering services for neffy, ensuring swift access upon availability, expected in late September. Recently, the U.S. Food and Drug Administration, FDA, approved neffy for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
- ARS Pharmaceuticals announces EC approval for EURneffy
- Medtronic, Palo Alto Networks report quarterly beats: Morning Buzz
- Vornado upgraded, JPMorgan downgraded: Wall Street’s top analyst calls
- Cantor starts ARS at Overweight, sees 111% potential upside
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue